2B70:XETRA:XETRA-iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) (EUR)

ETF | Others |

Last Closing

USD 5.88

Change

+0.01 (+0.12)%

Market Cap

USD 0.52B

Volume

0.06M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-14 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

-0.09 (-0.17%)

USD 448.39B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

-0.04 (-0.23%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

-0.12 (-0.46%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

-0.05 (-0.16%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

-0.08 (-0.32%)

USD 157.79B
TM5:XETRA T-MOBILE US INC.DL-00001

-0.04 (-0.03%)

USD 126.93B
JARI:XETRA Amundi Index Solutions - Amund..

-0.09 (-0.20%)

USD 105.55B
8R80:XETRA Amundi Index Solutions - Amund..

-0.48 (-0.34%)

USD 105.05B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

-0.11 (-0.22%)

USD 85.64B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

-1.38 (-0.27%)

USD 80.38B

ETFs Containing 2B70:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.05% 35% F 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.05% 35% F 38% F
Trailing 12 Months  
Capital Gain 6.43% 39% F 44% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.43% 39% F 43% F
Trailing 5 Years  
Capital Gain 39.85% 57% F 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 39.85% 55% F 57% F
Average Annual (5 Year Horizon)  
Capital Gain 6.45% 61% D- 60% D-
Dividend Return 6.45% 60% D- 57% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 14.52% 42% F 53% F
Risk Adjusted Return 44.44% 56% F 59% D-
Market Capitalization 0.52B 68% D+ 60% D-

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.